

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies (as amended)		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Sir:

A review of the official electronic file for this application reveals that an Information Disclosure Statement filed on 1 May 2003 is missing from the Office's records. This paper transmits a copy of the missing IDS, including the postcard receipt showing that the Office did in fact receive the submission when it was filed.

Applicant particularly calls the examiner's attention to this IDS as it provides documents cited by the European Patent Office in a counterpart application, EP 99960232. For the convenience of the Office, copies of the cited references accompany this paper.

Applicant believes that because this is a copy of a paper previously submitted, no fee is due. However, should any fee be required to render this paper timely or proper, applicant requests that the Director charge the required fee to our Deposit Account No. 18-1260.

Respectfully submitted,


/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	White, et al.)	<u>Certificate of Mailing</u>
Serial No.	09/436,347)	I, Patricia Munoz, hereby certify that this paper or fee is being deposited with the United States Postal Service as Express Mail Post Office to Addressee service (Mailing Label No. EU 491 361 435 US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Commissioner for Patents Post Office Box 1450, Alexandria, Virginia 22313-1450.
Filed:	November 9, 1999)	
For:	TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD 20 ANTIBODY)	By:  Patricia Munoz
Art Unit:	1643)	Date: <u>May 1, 2003</u>
Examiner:	To be assigned)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicants' duty under 37 C.F.R. §§1.97–98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies of the references are attached for the Examiner's convenience.

These references were cited in the European Search Report for EP 99 96 0232, which is related to the present application in that it claims priority from, *inter alia*, an earlier filed United States application. A copy of the European Search Report is attached.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR §1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 C.F.R. §1.97(h)), or even qualifies as "prior art" under 35 U.S.C. §102 with respect to this invention unless specifically designated by Applicants as such.

70038323v1 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /AH/
COPY

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 C.F.R. §1.56, exists.

The Commissioner is hereby authorized to charge any fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0278069.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By 
Suzanne L. Biggs
Registration No. 30,158

Dated: May 1, 2003

Address all correspondence to:
11682 El Camino Real, Suite 200
San Diego, CA 92130
Tel: (858) 509-4095
Fax: (858) 509-4010

Atty. Dkt. No.	Mr. [REDACTED]	Client Ref. # [REDACTED]
	037003-0278069	1998-30-0525CP1

Applicant: White, et al.

Appn. No.: 09/436,347

Filing Date: November 9, 1999

Examiner: To be assigned | Group Art Unit: 1643

Date: May 1, 2003

Page **1** of **1**

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						
FR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
GR									
HR									
IR									
JR									
KR									

OTHER (Indicate in this column other Title, Periodical Name, Date, References, etc.)

LR	Jensen, M., et al., Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDE-C2B8, rituximab), Ann. Hematol. 77:89-91 (1998)		
MR	McLaughlin, P., et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, Journal of Clinical Oncology, 16(8):2825-2833 (1998)		
NR	Malony, D., et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 90(6):2188-2195 (September 15, 1997)		
OR	Vartholomatos, G., et al., Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia, Acta Haematol. 102:94-98 (1999)		
PR			
QR			

Examiner / Alana M. Harris / Date Considered: April 11, 2008

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /AH/

COPY



POST OFFICE TO ADDRESSEE



**SEE REVERSE SIDE FOR
SERVICE GUARANTEE AND
INSURANCE COVERAGE LIMITS**



ORIGIN (POSTAL USE ONLY)		
PO ZIP Code <i>162</i>	Day of Delivery <input type="checkbox"/> Next <input checked="" type="checkbox"/> Second <input type="checkbox"/> Third	Flat Rate Envelope <input checked="" type="checkbox"/>
Date In <i>Mo. Day Year</i>	Postage <i>\$ 7.00</i>	
	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	
Time In <input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Return Receipt Fee	
Weight <i>.02 lbs.</i>	Int'l Alpha Country Code <i>1</i>	COD Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials <i>JL</i>	Insurance Fee
	Total Postage & Fees <i>\$ 7.00</i>	

CUSTOMER USE ONLY

METHOD OF PAYMENT

Express Mail Corporate Acct. No. *X*

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT) *John Doe* PHONE (*555-1234*)

TO: (PLEASE PRINT) *John Doe* PHONE (*555-1234*)

ZIP + 4 +

FOR PICKUP OR TRACKING CALL 1-800-222-1811

www.usps.com



PAT-103 8/01 PTO RECEIPT FOR INDICATED ITEMS

Ser No: 09/436,347

Atty Biggs, SL

Date 05/01/03

C# 037003

Inventor(s) White, et al.

Title: TREATMENT OF HEMATOLOGIC MALIGNANCIES
ASSOCIATED WITH CIRCULATING TUMOR CELLS USING
CHIMERIC ANTI-CD 20 ANTIBODY

M# 0278069

ENCLOSED:

Amendment Change of Address Notice

_____ No. of Pages Abstract

_____ No. of Pages Spec and Claims

_____ No. of numbered Claims only

Declaration(s) (_____ #pgs)

Assignment(s) (_____ sheets) Cover Sheet

_____ No. of Priority Documents

IDS Letter cited Appl(s). Foreign sch rpt/ent

PTO-1449 cited docs. Nonpublication Request

\$ _____ Fee (Check No. _____)

Other: Express Mail Label No. EU 491361435 US; Return Postcard



EU 491361435 US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /AH
COPY